технические задания для краски для внутренних работ
Главное меню:
Интересное
технические задания для краски для внутренних работ, Clinical efficacy and mechanisms of biologics for chronic , Tezspire for Nasal Polyps: A New Targeted Therapy on the , Dupixent® (dupilumab) Demonstrated Superiority Over Xolair , Efficacy and Safety of Biologics for Chronic Rhinosinusitis , Dupixent Outperforms Xolair in First-Ever Head-to-Head Trial , , .
Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). With recent regulatory approvals, there has been a surge in real-world studies (RWSs). This systematic review and meta-analysis aimed to summarise the efficacy and safety of these four biologics in real-world settings. Primary outcomes were nasal polyp score and sino-nasal outcome test-22 score. Secondary outcomes included smell identification test score, loss of smell score, nasal congestion score, overall nasal symptom score, treatment response, and adverse events (AEs) prompting discontinuation. Efficacy outcomes at 4, 6, 12, and over 12 months were summarised, and meta-analyses of mean changes from baseline were conducted. Sixty-four RWSs involving 3921 patients were included. Significant improvements in clinical outcomes were observed at most follow-up time points, with dupilumab showing particularly notable effects. The efficacy observed in these RWSs was superior to that demonstrated in phase 3 RCTs. All biologics exhibited low discontinuation rates due to AEs. Overall, biologic treatments for CRSwNP in real-world settings demonstrate strong efficacy and good safety. However, the limitations in current RWSs highlight the need for long-term, high-quality multicentre prospective studies and comprehensive healthcare database analyses., outcomes of biologic therapy versus endoscopic sinus surgery, and discuss therapies in development and future directions. (J Allergy Clin Immunol 2025;155:1401-10.) Key words: Chronic rhinosinusitis, nasal polyp, CRSwNP, CRSsNP, biologic, benralizumab, dupilumab, mepolizumab, omalizumab, tezepelumab Chronic rhinosinusitis (CRS) encompasses a , June 17, 2025. Tezspire for Nasal Polyps: A New Targeted Therapy on the Horizon. June 17, 2025. Anaphylm: The Needle-Free Epinephrine. June 4, 2025. FDA Warning: Stopping Zyrtec or Xyzal May Cause Rebound Itching—What Allergy Patients Need to Know. June 3, 2025. How the Palisades and Altadena Fires Are Affecting Your Sinuses, Lungs, and Long .
TARRYTOWN, N.Y. and PARIS, June 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma., Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). With recent regulatory approvals, there has been a surge in real-w …, Key achievements include a 1.60-point greater reduction in nasal polyp size and an 8.0-point superior improvement in smell identification compared to Xolair. Dupixent also showed significant advantages in nasal congestion reduction, symptom severity, and quality of life measures., , , .